Semaglutide
Safe body-fat decline supporting surgical/laser windows.
SC injection (abdomen) — 0.25 mg SC weekly starting dose, titrated up to ~2.4 mg weekly over 8+ weeks; compounded semaglutide in 12 mg multi-dose vials reaching 2.4 mg/week by 2–3 months
What It Is
Semaglutide is a GLP-1 receptor agonist (brand names Ozempic, Wegovy) that mimics the gut's incretin hormone. It enhances insulin secretion, suppresses glucagon, slows gastric emptying, and increases satiety. FDA-approved for type 2 diabetes and obesity management.
Mechanism
Semaglutide mimics GLP-1 incretin hormones, leading to reduced appetite, slower gastric emptying, and improved insulin secretion — resulting in significant weight loss. Importantly, it also reduces systemic inflammation (by weight loss and direct effects) and improves metabolic markers like HbA1c. By signaling fullness and steadying post-meal glucose, it helps reprogram metabolic balance. GLP-1 agonists also integrate into hormonal optimization plans, complementing therapies like testosterone or thyroid management.
How Dr. Emer Uses It
In Dr. Emer's practice, GLP-1 agonists are strategically deployed for pre- and post-surgical metabolic reset. Before body contouring, a GLP-1 analog can reduce visceral fat and inflammation, optimizing surgical safety; after liposculpture, it helps prevent fat rebound and metabolic "chaos" as the patient heals. In the "50-Year-Old Male, Metabolic Reset Archetype," Tirzepatide (5 mg weekly) or semaglutide is the anchor for potent weight loss and glycemic control. Protocols often begin with a fractional dose of GLP-1 analog (e.g. 0.25 mg semaglutide or less), escalated gradually over 4–8 weeks.
Key Benefits
- ✓Enhances insulin secretion and suppresses glucagon for glycemic control
- ✓Slows gastric emptying and increases satiety for significant weight loss
- ✓Reduces systemic inflammation via weight loss and direct anti-inflammatory effects
- ✓Pre-surgical metabolic prehabilitation — reduces visceral fat and liver fat
- ✓Post-contouring maintenance to prevent fat rebound hyperphagia
- ✓Improves HbA1c, inflammatory markers, and cardiovascular risk factors
Pairs Well With
Used In Programs
Safety & Considerations
FDA-approved for chronic weight management in obese patients. Main side effects: GI upset (nausea, reflux), risk of gallstones due to rapid weight loss, and a thyroid C-cell tumor warning (in rodents — though no human thyroid cancers seen; avoid in personal/family history of medullary thyroid carcinoma). Monitor weekly weight, glucose trends, and symptom logs (appetite, nausea). If patients experience intolerable nausea or plateau in effect, dosing is adjusted or paused per R/B/A evaluation.
Begin Your RECODEX™ Protocol
All peptide therapies are prescribed under direct medical supervision.
Book a Consultation
